The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

NS5a Replication Complex Inhibitor Will Be Used in Future Studies

Back to News Homepage

Next

When Hepatitis C Drugs Impact Your Thyroid

A New Combination of Hepatitis C Drugs Leading to High Remission Rates

October 16, 2013

Print this page

In phase 2 trials, the addition of the drug danoprevir to the current treatment regimen for patients with Hepatitis C showed an 85 percent sustained virologic response rate.

New hepatitis C drug shows potential in phase 2 trials

Posted By News On October 10, 2013

Bethesda, MD — The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin.

“Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events,” said Patrick Marcellin, lead study author from the Service d’Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. “The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease.”

Continue reading this entire article:
http://www.sciencecodex.com/new_hepatitis_c_drug_shows_potential_in_phase_2_trials-120853

3 Comments
Share
Share

Previous

NS5a Replication Complex Inhibitor Will Be Used in Future Studies

Back to News Homepage

Next

When Hepatitis C Drugs Impact Your Thyroid

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • Brama

    Peg and Riba? Snake oil compared to what is on the horizon in the next year or so. By now, if you’re still dealing with peg and riba, you’re in the dark ages of Hep C treatments.

    • trotter

      Nothing else is approved right now, it all is still junk added to Riba and Interferon. If that didn’t work at all for you, adding something to it does not help in the majority of cases. And, I still haven’t seen anything that they are trying once you get cirrhosis, they don’t even let you in a clinical trial 95% of the time because that would lower the SVR they keep trying to brag about.
      Yes, soon there will be better treatment, but the pharm. companies did nothing of importance for about 10 years. Why? They did not think it was cost-effective. We still need to apply pressure to them and get the public involved. Just my ideas.

  • scott gebhardt

    I did the Gilead 7977 + Ribavarin study started in Jan 2013 showed zero detection 1 month later, been off treatment since June 2013 still showing ZERO no bad side effects like the rat poison Interferon combo stuff, go back for another blood test in December,, fingers crossed